<DOC>
	<DOCNO>NCT01790893</DOCNO>
	<brief_summary>The purpose study monitor safety outcomes patient treated intravitreal aflibercept injection choroidal neovascularization secondary Presumed Ocular Histoplasmosis Syndrome .</brief_summary>
	<brief_title>Treatment Presumed Ocular Histoplasmosis</brief_title>
	<detailed_description />
	<mesh_term>Choroidal Neovascularization</mesh_term>
	<mesh_term>Histoplasmosis</mesh_term>
	<criteria>Active choroidal neovascularization ( CNV ) secondary presume ocular histoplasmosis demonstrate active leakage fluorescein angiography spectal domain OCT evidence subretinal intraretinal fluid PED . Active CNV may also define demonstrate active subretinal hemorrhage . ETDRS Best correct visual acuity 20/2020/320 . willing able comply study clinic visit study related procedure . Willing use practice one form contraceptives 13 month study male female . Provide sign informed consent Able understand complete study relate questionnaire Under 18 year age CNV due cause Presumed Ocular Histoplasmosis Previous treatment study eye within 6 month prior Day 1 More 5 Intravitreal injection antiVEGF therapy within previous 12 month Any clinical evidence ocular condition Ocular histoplasmosis History allergy fluorescein Pregnant ( plan become pregnant within next 13 month ) breast feed woman Sexually Active Men Women NOT willing practice one form contraceptives next 13 month . Anticipated previous ( within previous 3 month ) systemic antiVEGF therapy</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2014</verification_date>
	<keyword>Histoplasmosis</keyword>
</DOC>